The global hip osteoarthritis pain medicine market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of osteoarthritis and its associated pain in the elderly population, which is expected to increase the demand for hip osteoarthritis pain medicines.
Oral medications are expected to be the most popular type of treatment for hip osteoarthritis pain, with a share of over 50% in terms of revenue by 2030. Injection treatments are also expected to grow at a CAGR of 6%, owing to their ease-of-use and efficacy in treating chronic conditions such as arthritis. External treatments are also anticipated to grow at a CAGR of 4%.
-The number of people with hip osteoarthritis is expected to increase by more than 50% in the next 20 years.
-Hip osteoarthritis pain medicine is a growing market as it is one of the most common causes of disability in adults over 45 years old.
-The global hip osteoarthritis pain medicine market size was valued at $1,890 million in 2016 and is projected to reach $2,907 million by 2022.
-In 2016, the US accounted for about 40% of total global sales for hip osteoarthritis pain medicines and this share will continue to grow due to aging population and increasing incidence rates of this condition in the country.
-Increasing prevalence rates are also driving growth as well as an increased awareness among patients about treatment options available for this condition.
Industry Growth Insights published a new data on “Hip Osteoarthritis Pain Medicine Market”. The research report is titled “Hip Osteoarthritis Pain Medicine Market research by Types (Oral, Injection, External), By Applications (Medical Care, Personal Care), By Players/Companies Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hip Osteoarthritis Pain Medicine Market Research Report
By Type
Oral, Injection, External
By Application
Medical Care, Personal Care
By Companies
Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Hip Osteoarthritis Pain Medicine Market Report Segments:
The global Hip Osteoarthritis Pain Medicine market is segmented on the basis of:
Types
Oral, Injection, External
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medical Care, Personal Care
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Johnson & Johnson
- GlaxoSmithKline
- Bayer
- Eli Lilly
- Novartis
- Sanofi
- Horizon Pharma
- Abbott
- Mylan
- Daiichi Sankyo
- TEVA
- Almatica Pharma
- Astellas Pharma
- Tide Pharmaceutical
- Iroko Pharmaceuticals
- Hengrui Pharmaceutical
- Abiogen Pharma
Highlights of The Hip Osteoarthritis Pain Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- External
- By Application:
- Medical Care
- Personal Care
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hip Osteoarthritis Pain Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hip Osteoarthritis Pain Medicine is a type of medication that helps relieve pain and inflammation in the hip joint. It can be used to treat both acute (short-term) and chronic (long-term) hip pain.
Some of the major players in the hip osteoarthritis pain medicine market are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma.
The hip osteoarthritis pain medicine market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hip Osteoarthritis Pain Medicine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hip Osteoarthritis Pain Medicine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hip Osteoarthritis Pain Medicine Market - Supply Chain
4.5. Global Hip Osteoarthritis Pain Medicine Market Forecast
4.5.1. Hip Osteoarthritis Pain Medicine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hip Osteoarthritis Pain Medicine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hip Osteoarthritis Pain Medicine Market Absolute $ Opportunity
5. Global Hip Osteoarthritis Pain Medicine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Injection
5.3.3. External
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hip Osteoarthritis Pain Medicine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
6.3.1. Medical Care
6.3.2. Personal Care
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hip Osteoarthritis Pain Medicine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hip Osteoarthritis Pain Medicine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hip Osteoarthritis Pain Medicine Demand Share Forecast, 2019-2026
9. North America Hip Osteoarthritis Pain Medicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
9.4.1. Medical Care
9.4.2. Personal Care
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Injection
9.7.3. External
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hip Osteoarthritis Pain Medicine Demand Share Forecast, 2019-2026
10. Latin America Hip Osteoarthritis Pain Medicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
10.4.1. Medical Care
10.4.2. Personal Care
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Injection
10.7.3. External
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hip Osteoarthritis Pain Medicine Demand Share Forecast, 2019-2026
11. Europe Hip Osteoarthritis Pain Medicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
11.4.1. Medical Care
11.4.2. Personal Care
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Injection
11.7.3. External
11.8. Basis Point Share (BPS Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hip Osteoarthritis Pain Medicine Demand Share, 2019-2026
12. Asia Pacific Hip Osteoarthritis Pain Medicine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
12.4.1. Medical Care
12.4.2. Personal Care
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Injection
12.7.3. External
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hip Osteoarthritis Pain Medicine Demand Share, 2019-2026
13. Middle East & Africa Hip Osteoarthritis Pain Medicine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Application
13.4.1. Medical Care
13.4.2. Personal Care
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hip Osteoarthritis Pain Medicine Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Injection
13.7.3. External
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hip Osteoarthritis Pain Medicine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hip Osteoarthritis Pain Medicine Market: Market Share Analysis
14.2. Hip Osteoarthritis Pain Medicine Distributors and Customers
14.3. Hip Osteoarthritis Pain Medicine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Johnson & Johnson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bayer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Horizon Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Abbott
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Daiichi Sankyo
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. TEVA
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Almatica Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Astellas Pharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Tide Pharmaceutical
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Iroko Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Hengrui Pharmaceutical
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Abiogen Pharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
